P. Imbach

发表

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis

G. Martiny-Baron, Philipp Holzer, E. Billy, 2010, Angiogenesis.

Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.

P. Furet, P. Imbach, G. Bold, 2010, Genes & cancer.

A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome.

P. Furet, P. Imbach, M. Lang, 2001, Bioorganic & medicinal chemistry letters.

Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design.

P. Furet, P. Imbach, M. Lang, 2004, Journal of medicinal chemistry.

Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

P. Furet, P. Imbach, M. Lang, 2007, Bioorganic & Medicinal Chemistry Letters.

Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.

P. Imbach, D. Bierer, M. Reed, 1998, Journal of medicinal chemistry.

Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.

P. Imbach, G. Reaven, D. Bierer, 1998, Journal of medicinal chemistry.

Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

P. Furet, P. Imbach, M. Lang, 2002, Bioorganic & medicinal chemistry letters.

2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.

P. Furet, P. Imbach, H. Mett, 1999, Bioorganic & medicinal chemistry letters.

Structure-based design of potent CDK1 inhibitors derived from olomoucine

Thomas Meyer, Hans-Georg Capraro, Pascal Furet, 2000, J. Comput. Aided Mol. Des..

Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design.

P. Furet, P. Imbach, M. Lang, 2001, Bioorganic & medicinal chemistry letters.

Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings

M. Schirle, Philipp Holzer, P. Imbach, 2023, bioRxiv.